Table 3 Adjusted odds ratios (OR) and 95%CI describing factors associated with wait times from diagnosis to definitive surgery (n = 1,675), and from final surgery to postoperative chemotherapy (n = 498) or postoperative radiotherapy (n = 812)
From: Factors associated with wait times across the breast cancer treatment pathway in Ontario
Diagnosis → Definitive surgerya(n = 1,675) | Surgery to chemotherapyb(n = 498) | Surgery to radiotherapyc( n = 812) | |||||||
|---|---|---|---|---|---|---|---|---|---|
Wait time ≤17 days n (%) | Wait time >17 days n (%) | Odds ratio (95% CI) | Wait time ≤44 days n (%) | Wait time >44 days n (%) | Odds ratio (95% CI) | Wait time < 75 days n (%) | Wait time >75 days n (%) | Odds ratio (95% CI) | |
Detection Method | |||||||||
Screened | 527 (62.6) | 529 (63.5) | 1.00 reference | 155 (60.3) | 135 (56.0) | 1.00 reference | 281 (68.9) | 275 (68.1) | 1.00 reference |
Interval | 133 (15.8) | 160 (19.2) | 1.14 (0.86-1.51) | 50 (19.5) | 48 (19.9) | 1.01 (0.62-1.64) | 68 (16.7) | 64 (15.8) | 0.92 (0.60-1.38) |
Symptomatic | 182 (21.6) | 144 (17.3) | 0.93 (0.71-1.24) | 52 (20.2) | 58 (24.1) | 1.35 (0.84-2.19) | 59 (14.5) | 65 (16.1) | 1.09 (0.70-1.68) |
Age at Diagnosis | |||||||||
50-59 | 364 (43.2) | 285 (34.2) | 1.00 reference | 129 (50.2) | 97 (40.3) | 1.00 reference | 155 (38.0) | 125 (30.9) | 1.00 reference |
60-69 | 478 (56.8) | 548 (65.8) | 0.97 (0.67-1.40) | 128 (49.8) | 144 (59.8) | 1.45 (0.98 -2.14) | 253 (62.0) | 279 (69.1) | 1.12 (0.82-1.55) |
Diagnosis Year | |||||||||
1995-1999 | 555 (65.9) | 374 (44.9) | 1.00 reference | 141 (54.9) | 100 (41.5) | 1.00 reference | 281 (68.9) | 197 (48.8) | 1.00 reference |
2000-2003 | 287 (34.1) | 459 (55.1) | 2.29 (1.85-2.86)* | 116 (45.1) | 141 (58.5) | 1.62 (1.10-2.41)‡ | 127 (31.1) | 207 (51.2) | 2.55 (1.86-3.52)* |
Income Quintile | |||||||||
Q1 (poorest) | 167 (20.0) | 130 (15.7) | 1.00 reference | 45 (17.7) | 44 (18.5) | 1.00 reference | 63 (15.6) | 72 (18.0) | 1.00 reference |
Q2 | 140 (16.8) | 165 (20.0) | 1.49 (1.05-2.09)‡ | 40 (15.7) | 48 (20.2) | 1.26 (0.68-2.34) | 78 (19.3) | 65 (16.2) | 0.68(0.41-1.12) |
Q3 | 162 (19.4) | 155 (18.8) | 1.21 (0.86-1.71) | 52 (20.4) | 42 (17.7) | 0.78 (0.42-1.45) | 68 (16.8) | 85 (21.2) | 0.90 (0.54-1.48) |
Q4 | 154 (18.4) | 178 (21.6) | 1.47 (1.05-2.06)‡ | 54 (21.2) | 48 (20.2) | 0.96 (0.53-1.75) | 77 (19.0) | 87 (21.7) | 0.84 (0.51-1.38) |
Q5 (richest) | 212 (25.4) | 198 (24.0) | 1.16 (0.84-1.61) | 64 (25.1) | 56 (23.5) | 0.84 (0.47-1.50) | 119 (29.4) | 92 (22.9) | 0.60 (0.37-0.96)† |
Treatment Centre Region | |||||||||
South Central | 423 (50.2) | 332 (39.9) | 1.00 reference | 123 (47.9) | 99 (41.1) | 1.00 reference | 156 (38.2) | 199 (49.3) | 1.00 reference |
South Eastern | 155 (18.4) | 253 (30.4) | 1.96 (1.51-2.56)* | 60 (23.4) | 76 (31.5) | 1.76 (1.12-2.78)∂ | 129 (31.6) | 68 (16.8) | 0.40 (0.27-0.58)* |
South Western | 137 (16.3) | 173 (20.8) | 1.36 (1.03-1.81)† | 31 (12.1) | 41 (17.0) | 1.67 (0.94-2.94) | 58 (14.2) | 102 (25.3) | 1.24 (0.83-1.87) |
Northern | 127 (15.1) | 75 (9.0) | 0.57 (0.41-0.81)* | 43 (16.7) | 25 (10.4) | 0.59 (0.32-1.09) | 65 (15.9) | 35 (8.7) | 0.33 (0.20-0.55)* |
TNM Stage | |||||||||
1 | 432 (51.3) | 460 (55.2) | 1.00 reference | 57 (22.2) | 46 (19.1) | 1.00 reference | 323 (79.2) | 312 (77.2) | 1.00 reference |
2 | 296 (35.2) | 284 (34.1) | 0.86 (0.68-1.08) | 138 (53.7) | 132 (54.8) | 1.15 (0.69-1.88) | 80 (19.6) | 83 (20.5) | 1.18 (0.80-1.74) |
3 | 114 (13.5) | 89 (10.7) | 0.49 (0.34-0.71)* | 62 (24.1) | 63 (26.1) | 1.19 (0.66-2.13) | 5 (1.2) | 9 (2.2) | 2.83 (0.74-10.8) |